Somerset, N.J. – November 6, 2018 — Catalent Pharma Solutions, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced that two of its experts have been invited to speak at the upcoming Waterside Conference, to be held at the Hilton Norfolk The Main Hotel, Norfolk, Virginia, on Nov. 12 – 14, 2018.
On Tuesday, Nov. 13, 8:30-9:15 a.m., Emily Schirmer, Ph.D., Director, Downstream Process Development, Catalent Biologics, will present “Continuous Processing in Biomanufacturing: Case Studies in Biologic Development Scale-Down Models and Manufacturing,” in the Process Analysis & Automation track. Dr. Schirmer will use a case study to compare the productivity of purification in batch mode versus continuous mode.
On Wednesday, Nov. 14 at 9:15-10:00 a.m., Greg Bleck, Ph.D., Global Head of Research and Development, Catalent Biologics, will present “Efficient Expression of Complex Proteins in Mammalian Cells,” in the Expansion & Expression Track. Dr. Bleck will discuss the use and advantages of Catalent’s GPEx® technology for cell line development.
Dr. Schirmer joined Catalent in 2015 and is responsible for the development of downstream processes which enable the production of pre-clinical and cGMP products, as well as process characterization and late-stage development. Before joining Catalent, Dr. Schirmer worked at Illumina where she created capabilities to scale-up downstream processes. Prior to this, she worked at startup companies in Cambridge, Massachusetts developing and transferring downstream processes for the clinical manufacture of antibodies and recombinant proteins. Dr. Schirmer received her bachelor’s degree in chemical engineering from the University of Delaware, and her master’s degree and doctorate in chemical engineering from the University of Virginia.
At Catalent, Dr. Bleck has overall responsibility for the development and acquisition of new products and technologies. He was an original employee of Gala Biotech (acquired by Catalent), where he used his knowledge of gene expression and transgenic systems to develop and optimize retrovector expression systems and the proprietary GPEx process. Prior to joining Gala, he performed postdoctoral work at the University of Illinois-Urbana working in the areas of gene regulation and expression. Dr. Bleck holds a bachelor’s degree and a doctorate in endocrinology-reproductive physiology, both from the University of Wisconsin-Madison. He has published over 60 research papers, co-authored three book chapters, and is an inventor or co-inventor on eight issued patents and eight patents currently under review.
For more information visit The Waterside Conference event page.
To arrange a meeting with any of the attending Catalent executives at the event, contact Richard Kerns at NEPR - email@example.com.
+44 (0)7580 041073
+44 (0) 161 728 5880
About Catalent Biologics
Catalent Biologics provides advanced technologies and tailored solutions for biologic and biosimilar development, from DNA to commercial supply, through our extensive Biologics network including: Madison, Wisconsin; Emeryville, California; Kansas City, Missouri; Morrisville, North Carolina and Bloomington, Indiana. For more information on Catalent Biologics, visit Biologics.Catalent.com
Catalent is the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products. With 85 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable clinical and commercial product supply. Catalent employs over 11,000 people, including over 1,800 scientists, at more than 30 facilities across five continents, and in fiscal 2018 generated approximately $2.5 billion in annual revenue. Catalent is headquartered in Somerset, New Jersey. For more information, visit www.catalent.com.